RGNX Stock Overview
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
REGENXBIO Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.19 |
| 52 Week High | US$28.80 |
| 52 Week Low | US$11.83 |
| Beta | 1.32 |
| 1 Month Change | -27.01% |
| 3 Month Change | 27.28% |
| 1 Year Change | -16.37% |
| 3 Year Change | -53.33% |
| 5 Year Change | -68.61% |
| Change since IPO | -46.83% |
Recent News & Updates
REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%
Apr 25
Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform
Mar 11Recent updates
REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%
Apr 25Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform
Mar 11Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers
Mar 07Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified
Mar 05Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Mar 02Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips
Jan 19There's No Escaping REGENXBIO Inc.'s (NASDAQ:RGNX) Muted Revenues
Dec 21We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully
Nov 09Will REGENXBIO (NASDAQ:RGNX) Spend Its Cash Wisely?
Aug 08REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Trimmed Their Revenue Forecasts By 12%
May 11Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation
May 08Analysts Are More Bearish On REGENXBIO Inc. (NASDAQ:RGNX) Than They Used To Be
Mar 05REGENXBIO says additional phase 2 data bolsters RGX-314 for wet macular degeneration
Oct 03Regenxbio: A Transformative Year
Sep 15Regenxbio: Updates To Thesis, Gene Therapy Pioneer Moving To Late-Stage Development
Aug 29Regenxbio to seek FDA's accelerated approval for Hunter Syndrome treatment, shares rise 8%
Aug 03Regenxbio: Patience And Regular Homework Are Keys
Jul 12REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Slashed This Year's Estimates
Jun 27The Strong Earnings Posted By REGENXBIO (NASDAQ:RGNX) Are A Good Indication Of The Strength Of The Business
May 12Shareholder Returns
| RGNX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.2% | 0.4% | 1.0% |
| 1Y | -16.4% | 0.9% | 21.9% |
Return vs Industry: RGNX underperformed the US Biotechs industry which returned 0.9% over the past year.
Return vs Market: RGNX underperformed the US Market which returned 21.9% over the past year.
Price Volatility
| RGNX volatility | |
|---|---|
| RGNX Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RGNX's share price has been volatile over the past 3 months.
Volatility Over Time: RGNX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 344 | Ken Mills | www.regenxbio.com |
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
REGENXBIO Inc. Fundamentals Summary
| RGNX fundamental statistics | |
|---|---|
| Market cap | US$794.00m |
| Earnings (TTM) | -US$263.49m |
| Revenue (TTM) | US$90.24m |
8.8x
P/S Ratio-3.0x
P/E RatioIs RGNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGNX income statement (TTM) | |
|---|---|
| Revenue | US$90.24m |
| Cost of Revenue | US$266.48m |
| Gross Profit | -US$176.24m |
| Other Expenses | US$87.26m |
| Earnings | -US$263.49m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.37 |
| Gross Margin | -195.29% |
| Net Profit Margin | -291.99% |
| Debt/Equity Ratio | 30.2% |
How did RGNX perform over the long term?
See historical performance and comparison